Structure Therapeutics (NASDAQ:GPCR) Earns Market Outperform Rating from JMP Securities

JMP Securities reiterated their market outperform rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a report released on Monday,Benzinga reports. They currently have a $89.00 price target on the stock.

Other research analysts have also issued reports about the stock. HC Wainwright cut their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Monday, May 12th. William Blair started coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating for the company. Finally, Citigroup began coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a “buy” rating and a $60.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $76.17.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $21.79 on Monday. The firm has a fifty day moving average price of $23.46 and a two-hundred day moving average price of $24.04. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -25.05 and a beta of -1.87. Structure Therapeutics has a one year low of $13.22 and a one year high of $47.48.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Equities research analysts expect that Structure Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several large investors have recently modified their holdings of the business. Mariner LLC bought a new position in Structure Therapeutics during the 4th quarter valued at approximately $665,000. Invesco Ltd. increased its stake in shares of Structure Therapeutics by 4.1% during the fourth quarter. Invesco Ltd. now owns 371,767 shares of the company’s stock valued at $10,082,000 after buying an additional 14,559 shares during the period. Barclays PLC increased its stake in shares of Structure Therapeutics by 42.6% during the fourth quarter. Barclays PLC now owns 115,671 shares of the company’s stock valued at $3,138,000 after buying an additional 34,533 shares during the period. GAMMA Investing LLC raised its holdings in shares of Structure Therapeutics by 663.8% during the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company’s stock valued at $152,000 after acquiring an additional 7,627 shares in the last quarter. Finally, Foresite Capital Management VI LLC purchased a new stake in Structure Therapeutics in the fourth quarter worth $11,390,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.